Icon (ICLR) Projected to Release Earnings on Tuesday

Key Points

• Icon is expected to report Q3 2026 results after Tuesday’s market close, with analysts projecting earnings of $2.63 per share on $2.01 billion in revenue. The earnings conference call is scheduled for October 28 at 8:00 a.m. ET.
• In its prior quarter, Icon earned $2.56 per share, narrowly beating estimates, while revenue rose 2.3% year over year to $2.06 billion; analysts forecast full-year EPS of $9.56.
• Wall Street’s consensus rating is Hold, with a $174.73 price target. The stock recently traded at $168.14, while insiders sold 22,796 shares worth approximately $3.89 million over the past quarter.

Icon (NASDAQ:ICLR - Get Free Report) is anticipated to issue its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect Icon to post earnings of $2.63 per share and revenue of $2.01 billion for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Icon (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The business had revenue of $2.06 billion during the quarter, compared to analysts' expectations of $2 billion. During the same quarter in the prior year, the company posted $3.26 EPS. The business's revenue for the quarter was up 2.3% on a year-over-year basis. On average, analysts expect Icon to post $9.56 EPS for the current fiscal year and $10.61 EPS for the next fiscal year.

Icon Stock Performance

Icon stock opened at $168.14 on Tuesday. The firm has a 50 day simple moving average of $167.44 and a 200-day simple moving average of $149.92. The stock has a market cap of $12.87 billion, a price-to-earnings ratio of 39.47, a price-to-earnings-growth ratio of 10.99 and a beta of 1.24. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. Icon has a 1-year low of $66.57 and a 1-year high of $203.91.

Insider Buying and Selling at Icon

In other news, Director Anne Whitaker sold 841 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total value of $138,167.89. Following the transaction, the director directly owned 891 shares in the company, valued at approximately $146,382.39. This represents a 48.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ronan Murphy sold 5,005 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $175.00, for a total transaction of $875,875.00. Following the transaction, the director directly owned 3,847 shares of the company's stock, valued at $673,225. The trade was a 56.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 22,796 shares of company stock valued at $3,887,139. 44.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. UBS Group assumed coverage on Icon in a report on Wednesday, September 30th. They issued a "neutral" rating and a $195.00 price objective on the stock. Zacks Research raised Icon from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. Robert W. Baird set a $194.00 target price on Icon in a research report on Friday, July 31st. Truist Financial restated a "buy" rating and issued a $209.00 target price (up from $207.00) on shares of Icon in a research report on Friday, July 31st. Finally, William Blair raised Icon to a "strong-buy" rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $174.73.

Icon Company Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.